Hematologic Malignancies

Expert faculty review and share their insights and perspectives on key findings in hematologic malignancies presented at the 2022 ASCO Annual Meeting.

Share

Program Content

Activities

  • Hematologic Malignancies Highlights: ASCO 2022
    Key Studies in Hematologic Malignancies: Independent Conference Coverage of the 2022 ASCO Annual Meeting
    Conference Coverage
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 13, 2022

    Expires: September 12, 2023

    View Activity

Activities

Glofitamab in R/R DLBCL
Pivotal Phase II Trial of Glofitamab in R/R DLBCL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2022

Expires: June 04, 2023

View Activity
ROSEWOOD
ROSEWOOD Primary Analysis: Phase II Trial of Zanubrutinib and Obinutuzumab vs Obinutuzumab Alone in R/R Follicular Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2022

Expires: June 05, 2023

View Activity
Ponatinib/Blinatumomab in ALL
Phase II Trial of Ponatinib + Blinatumomab in Adults With Ph+ ALL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2022

Expires: June 05, 2023

View Activity
SHINE
SHINE: First-line Ibrutinib + Bendamustine/Rituximab Followed by Rituximab Maintenance in Older Patients With MCL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2022

Expires: June 06, 2023

View Activity
ELEVATE-TN: 5-Yr Update
ELEVATE-TN: 5-Yr Update of Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil in Treatment-Naive CLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2022

Expires: June 06, 2023

View Activity
MajesTEC-1 Update
MajesTEC-1: Update From Phase I/II Trial of the BCMA x CD3 Bispecific Antibody Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2022

Expires: June 06, 2023

View Activity
ECHELON-1 OS Analysis
ECHELON-1: OS Analysis of First-line Brentuximab Vedotin + AVD vs ABVD in Advanced Classical Hodgkin Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2022

Expires: June 06, 2023

View Activity
GC012F Phase I
First-in-Human Study of GC012F: BCMA/CD19 Dual-Targeted CAR T-Cell Therapy for Relapsed/Refractory Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2022

Expires: June 08, 2023

View Activity
ATLAS: Post-ASCT KRd
Phase III ATLAS Trial of Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide Alone as Maintenance After ASCT in Patients With NDMM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2022

Expires: June 08, 2023

View Activity
ASCEND: 4-Yr Update
ASCEND: 4-Yr Follow-up Analysis of Acalabrutinib vs Rituximab + Idelalisib or Bendamustine in Relapsed/Refractory CLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2022

Expires: June 08, 2023

View Activity
ASCEMBL 96-Wk Update
ASCEMBL: 96-Wk Update of Asciminib vs Bosutinib for CML-CP Previously Treated With ≥2 TKIs
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2022

Expires: June 08, 2023

View Activity
DETERMINATION
DETERMINATION: Phase III Trial of VRd ± ASCT With Ongoing Lenalidomide Maintenance in Patients With NDMM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 10, 2022

Expires: June 09, 2023

View Activity
Magrolimab + Aza for AML
Phase Ib Trial of Frontline Anti-CD47 Antibody Magrolimab + Azacitidine in TP53-Mutated AML
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 10, 2022

Expires: June 09, 2023

View Activity
CAPTIVATE: FD Cohort 3-Yr Update
CAPTIVATE: 3-Yr Follow-up Analysis From the Fixed-Duration Cohort of First-line Ibrutinib + Venetoclax for CLL/SLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 10, 2022

Expires: June 09, 2023

View Activity
IDHENTIFY by <i>IDH2</i> Variant
Phase III IDHENTIFY Trial of Enasidenib vs Conventional Care in Late-Stage IDH2-Mutated R/R AML: Analysis by IDH2 Mutation
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 13, 2022

Expires: June 12, 2023

View Activity
Zilovertamab + Ibr in MCL or CLL
Phase I/II Trial of Zilovertamab, an Anti-ROR1 Antibody, Plus Ibrutinib in MCL or CLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 15, 2022

Expires: June 14, 2023

View Activity
Dual Anti–PD-1/Anti–LAG-3 in cHL
Phase I/II Study of Pembrolizumab + Favezelimab, an Anti–LAG-3 mAb, in R/R Classical Hodgkin Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 15, 2022

Expires: June 14, 2023

View Activity
EPCORE NHL-2: R/R FL
Epcoritamab, a CD3 x CD20 Bispecific Antibody, Plus R2 in R/R Follicular Lymphoma: Updated Analysis of Phase I/II EPCORE NHL-2 Trial
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 16, 2022

Expires: June 15, 2023

View Activity
EPCORE NHL-2: DLBCL
Epcoritamab, a CD3 x CD20 Bispecific Antibody, Plus R-CHOP in Untreated High-Risk DLBCL: Updated Analysis of Phase I/II EPCORE NHL-2 Trial
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 16, 2022

Expires: June 15, 2023

View Activity
Crenolanib + 7+3 in AML
Phase II Trial of Crenolanib and 7+3 Chemotherapy in Newly Diagnosed FLT3-Mutated AML: Long-term Results
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 17, 2022

Expires: June 16, 2023

View Activity
Pre-MEASURE: MRD in AML pre-alloHCT
Pre-MEASURE: Retrospective Analysis of the Prognostic Significance of NGS-MRD Testing in Patients With AML in First Remission Prior to Allogeneic HCT
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 17, 2022

Expires: June 16, 2023

View Activity
Mini-HCVD + INO ± Blina in B-ALL
Mini-HyperCVD + Inotuzumab Ozogamicin ± Blinatumomab in Older Adults With Newly Diagnosed Ph-Negative B-Cell ALL: Updated Phase II Results
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022
View Activity

Faculty

cover img faculity

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

cover img faculity

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

cover img faculity

Eunice S. Wang, MD

Chief, Leukemia/Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Gilead Sciences, Inc.

Novartis Pharmaceuticals Corporation

Seagen